Glyclada (Gliclazide)

Glyclada is indicated for the management of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

• As monotherapy in patients newly diagnosed with type 2 diabetes.
• In combination with metformin when additional glucose lowering is required.
• As part of a fixed‑dose combination regimen with other oral antidiabetics.
• For patients who retain some endogenous insulin secretion.
• To help achieve target HbA1c levels as determined by a healthcare professional.

The safety profile of Glyclada reflects the typical effects observed with sulfonylurea agents; side effects can range from mild and transient to rare but serious.

Common

• Mild to moderate hypoglycemia, presenting as shakiness, sweating, or hunger, particularly when meals are delayed.
• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Intermittent headache.
• Dizziness or a sensation of light‑headedness, often related to low blood glucose.

Serious

• Severe hypoglycemia with confusion, seizures, or loss of consciousness requiring medical attention.
• Allergic reactions including rash, itching, urticaria, or facial swelling.
• Hematologic effects such as reduced white blood cells (leukopenia) or platelets (thrombocytopenia).
• Hepatic abnormalities reflected by elevated liver enzymes or jaundice.

Before starting Glyclada, healthcare providers should evaluate several clinical factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function, as impairment may affect drug clearance.
• Review history of cardiovascular disease, since sulfonylureas can influence cardiac outcomes.
• Confirm that the patient has sufficient endogenous insulin production.
• Caution in elderly patients due to increased susceptibility to hypoglycemia.
• Advise patients to avoid alcohol excess, which can potentiate hypoglycemic episodes.
• Discuss pregnancy and lactation status; safety data are limited.

Glyclada may interact with other medicines, altering blood glucose levels or increasing the risk of adverse effects.

Avoid

• Concomitant use with other sulfonylureas or insulin that can cause severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliclazide concentrations.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may affect glucose tolerance.
• Anticoagulants, as glycemic fluctuations can influence INR stability.
• Oral contraceptives, which might modify gliclazide metabolism.